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Boca Raton Regional Hospital
• Not-for-profit 400 bed advanced academic tertiary medical center





– Emergency Medicine 
– Neurosciences
• Predominantly elderly patient population
• Highest ranked hospital in Palm Beach County 
– Listed by U.S. News & World Report 2019-2020
• Lynn Cancer Institute is one of the largest cancer programs in the state of Florida and 
accredited by the American College of Surgeons
Presentation Objective 
Identify the effect etomidate has on cortisol production
Background
During sepsis, pro-inflammatory markers stimulate the 
upregulation of cortisol release
An increase in cortisol production results in metabolic, 
cardiovascular, and anti-inflammatory benefits in order 
to maintain homeostasis during stress
A disruption in this mechanism causes primary adrenal 
insufficiency and a lack of adequate stress response
Prigent H, Maxime V, and Annane D. Science review: Mechanism of impaired adrenal function in sepsis and molecular action of glucocorticoids. Crit Care 2004;8:243-252.
Background
1. Amidate (etomidate) [package insert]. Lake Forest, IL: Hospira, Inc.;2017.
2. Thompson Baastin ML, Baker SN, and Weant KA. Effects of etomidate on adrenal suppression: A review of intubated septic patients. Hosp Pharm 2014;49(2):177-183.
11-deoxycortisol cortisol
• Etomidate is a short-acting, sedative hypnotic that is often used as an induction agent 
for rapid sequence intubation (RSI)1
• Etomidate inhibits the enzyme 11-β hydroxylase, which is responsible for the 
conversion of 11-deoxycortisol to cortisol2
• Reduced plasma cortisol levels have been reported with a typical induction dose (0.3 
mg/kg) of etomidate1
• Although the role of etomidate in adrenal suppression has been established, the 
clinical consequences of this mechanism are controversial2
11-β hydroxylase
Literature Evaluation
Study Design Arms Results




Etomidate vs. other 
induction agents
Induction agent did not affect 
duration (P = 0.54) or dose (P = 
0.53) of vasopressor therapy




Etomidate vs. other 
induction agents
No difference in the mean dose of 
vasopressor in norepinephrine 
equivalents (P = 0.61)




Etomidate vs. other 
induction agents
No difference in need for 
vasopressor support with etomidate 
vs. non-etomidate (P = 0.88)
1. Ray DC, et al. Effect of etomidate agent on vasopressor and steroid use, and outcome in patients with septic shock. Crit Care. 2007;11:R56.
2. Elliot M, et al. Does etomidate increase vasopressor requirements in patients needing mechanical ventilation? Can J Hosp Pharm. 2012;65(4):272-276.
3. Alday NJ, et al. Effects of etomidate on vasopressor use in patients with sepsis or severe sepsis: a propensity-matched analysis. J Crit Care. 2014;29(4):517-22.
Purpose
To analyze if etomidate exhibits a dose dependent effect 
on the duration of intravenous (IV) vasopressor support 
and other clinical outcomes in septic patients 
Study Outcomes
Primary outcome
• Duration of IV vasopressor support between low dose (≤ 0.3 mg/kg) 
and high dose (> 0.3 mg/kg) etomidate
Secondary outcomes
• Number of patients requiring initiation of stress dose steroids
• Intensive care length of stay
• Duration of mechanical ventilation 
• Inpatient mortality
Study Design
Methods: Retrospective chart review using an electronic medical record 
(EMR)-generated report from October 21, 2017 to December 31, 2019
Inclusion Criteria
• Age ≥ 18 years
• Differential diagnosis of 
sepsis or septic shock 
based on provider 
documentation
• Received etomidate as an 
induction agent for RSI
Exclusion Criteria
• History of an adrenal 
disorder
• Taking medications that 
directly impact adrenal 
function prior to admission
Statistical Analysis


























Interquartile range 63 – 86.5 75 – 87
Gender – no. (%)
Female 31 (39.2) 14 (66.7)
Weight – kg
Median 77 49.7






Primary outcome: median duration of IV vasopressor support was 32 
hours vs. 50.5 hours, P = 0.0455
Results
Secondary Outcomes Low-Dose(n = 79)
High-Dose
(n = 21)
Initiated on stress dose steroids – no. (%) 24 (30.4) 6 (28.6)
Intensive care length of stay – days 
Median 5 8
Interquartile range 3 – 12 5 – 10 
Duration of mechanical ventilation – days
Median 4 5
Interquartile range 2 – 9.5 4 – 8 
Inpatient mortality – no. (%) 27 (34.2) 5 (23.8)
Conclusion
There was a statistically significant difference in duration of IV 
vasopressor support between the low-dose and high-dose groups
Secondary outcome results were similar between the low-dose 
and high-dose groups
Despite the small sample size, the significant results of this study 
warrant the need for a randomized controlled trial to be conducted
Limitations
Inconsistent use of sepsis-3 criteria among providers
Limited provider documentation
Oral vasopressor support (i.e. midodrine) was not evaluated
Small sample size
Unequal treatment group sizes
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Self-Assessment Question
Which of the following correctly describes the effect etomidate 
has on cortisol production? 
A. Etomidate directly binds to cortisol, which makes it inactive.
B. Etomidate inhibits the enzyme 11-β hydroxylase, which is 
responsible for conversion of 11-deoxycortisol to cortisol.
C. Etomidate regulates cortisol production through a negative 
feedback mechanism.
D. Etomidate does not affect cortisol production.
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